| fullrecord |
[{"key": "dc.contributor.advisor", "value": "Tarkka, Ina", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Karvinen, Sira", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Jakoaho, Veera", "language": "", "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2020-06-26T05:30:06Z", "language": "", "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2020-06-26T05:30:06Z", "language": "", "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2020", "language": "", "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/70933", "language": "", "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Ik\u00e4\u00e4ntyminen lis\u00e4\u00e4 syd\u00e4n- ja verisuonitautien riski\u00e4. My\u00f6s vaihdevuosien aikaiset hormonimuutokset altistavat naiset ep\u00e4edullisille aineenvaihdunnan muutoksille, jotka tulisi erottaa ik\u00e4\u00e4ntymiseen liittyvist\u00e4 muutoksista. Suuri korkean tiheyden lipoproteiinin kolesterolin (HDL-C) m\u00e4\u00e4r\u00e4 on yhteydess\u00e4 pienemp\u00e4\u00e4n syd\u00e4n- ja verisuonitautiriskiin. HDL-C:n m\u00e4\u00e4r\u00e4 n\u00e4ytt\u00e4isi kasvavan vaihdevuosien aikana, mutta t\u00e4ll\u00f6in se ei anna suojaa syd\u00e4n- ja verisuonitaudeilta. Vaihdevuosien aikana korkean tiheyden lipoproteiinin (HDL) rakenteessa saattaakin tapahtua muutoksia, jotka vaikuttavat sen toimintaan. Proteiinien ja rasvojen lis\u00e4ksi HDL kuljettaa lyhyit\u00e4 RNA-molekyylej\u00e4, mikro-RNA:ita (miRNA), jotka s\u00e4\u00e4telev\u00e4t solujen toimintaa. Systeemisen estradiolitason (E2) on todettu vaikuttavan tiettyihin verenkierrossa kulkeviin miRNA:ihin, kuten miR-21, -126 ja -146a, joilla on yhteys my\u00f6s syd\u00e4n- ja verisuonitauteihin sek\u00e4 kest\u00e4vyyskuntoon. Estradiolipitoisuuden vaikutusta HDL:n kuljettamiin miRNA:ihin ei ole kuitenkaan tutkittu. T\u00e4m\u00e4n tutkimuksen tarkoituksena oli selvitt\u00e4\u00e4 vaihdevuosien hormonimuutosten vaikutusta HDL:n kuljettamiin miRNA:ihin tutkimalla hormonikorvaushoidon (HRT) vaikutusta miR-21, -126 ja -146a -tasoihin, sek\u00e4 selvitt\u00e4\u00e4 kyseisten miRNA:iden ja kest\u00e4vyyskunnon v\u00e4list\u00e4 yhteytt\u00e4. T\u00e4m\u00e4 tutkielma oli osa \u201dKeski-ik\u00e4isten naisten metabolisten toimintah\u00e4iri\u00f6iden riski: systeeminen ja intrakriininen estrogeeni sek\u00e4 mikro-RNA:t v\u00e4litt\u00e4vin\u00e4 tekij\u00f6in\u00e4\u201d (EsmiRs) -tutkimusta. Tutkimusjoukko koostui terveist\u00e4 vaihdevuodet ohittaneista HRT-k\u00e4ytt\u00e4jist\u00e4 (n = 5) sek\u00e4 ei-k\u00e4ytt\u00e4jist\u00e4 (n = 5). Aineenvaihduntasairauksien puuttuminen mahdollisti HRT:n vaikutusten tutkimisen ilman tautirasitetta. Tutkittavien kest\u00e4vyyskuntoa mitattiin maksimaalisella polkupy\u00f6r\u00e4ergometritestill\u00e4 ja se kuvattiin kuormituksessa saavutetun hapenkulutuksen huippuarvon (VO2peak) avulla. HDL eristettiin ennen testi\u00e4 otetuista seerumin\u00e4ytteist\u00e4 ja edell\u00e4 mainitut miRNA:t mitattiin k\u00e4ytt\u00e4en reaaliaikaista polymeraasiketjureaktioita (qPCR). Ryhmien v\u00e4lill\u00e4 ei ollut merkitsev\u00e4\u00e4 eroa HDL-C m\u00e4\u00e4r\u00e4ss\u00e4 eik\u00e4 HDL:n kuljettamissa miR-21, -126 ja -146a -tasoissa. miR-126 -tason ja E2 v\u00e4lill\u00e4 havaittiin positiivinen yhteys (p = 0.029). Tutkituista miRNA:ista ainoastaan miR-146a korreloi negatiivisesti VO2peak -arvojen kanssa HRT-k\u00e4ytt\u00e4jill\u00e4 (p = 0.037) sek\u00e4 kiihtyvyysmittarilla mitatun vapaa-ajan liikunnan kanssa ei-k\u00e4ytt\u00e4jill\u00e4 (p = 0.037). T\u00e4m\u00e4n tutkimuksen perusteella HRT:n k\u00e4ytt\u00f6 ei vaikuta HDL-C:n m\u00e4\u00e4r\u00e4\u00e4n eik\u00e4 HDL:n miR-21, -126 ja -146a tasoihin. Pienest\u00e4 otoskoosta huolimatta miR-126 ja E2 v\u00e4lill\u00e4 havaittiin yhteys ja tutkimustulos tukee aiemmin havaittua yhteytt\u00e4 miR-146a ja liikunnan v\u00e4lill\u00e4. Jatkossa tulisi tutkia tarkemmin vaihdevuosien hormonimuutosten vaikutusta HDL:n toimintaan.", "language": "fi", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Cardiovascular disease (CVD) risk increases with age. Also, menopause, a period when women undergo significant hormonal changes, predisposes to several unfavourable metabolic alterations which increase CVD risk and should be separated from age-related changes. Even though several studies show that high-density lipoprotein cholesterol (HDL-C) increases during menopause, it does not protect from CVD. Hence, high HDL-C levels may not always reduce CVD risk. High-density lipoprotein (HDL) may undergo compositional changes during menopause that affect its function. In addition to the protein and lipid cargo, HDL transports short RNA molecules, microRNAs (miRNAs), that regulate cell functions. Systemic estradiol (E2) level has previously been reported to affect specific circulating miRNAs, such as miR-21, -126 and -146a, which also associate with CVD and cardiorespiratory fitness (CRF). However, no study has examined the effects of serum E2 on HDL-carried miRNAs. The aim of this study was to examine the effects of menopausal hormonal changes on HDL-carried miRNAs by investigating the effects of hormone replacement therapy (HRT) on miR-21, -126 and 146a content of HDL and to examine the association between these miRNAs and CRF.\r\nThis study was part of \u201cthe Systemic and Intracrine Estrogen and MicroRNAs mediate the risk of metabolic dysfunction in middle-aged women\u201d (EsmiRs) study. Participants comprised of healthy postmenopausal HRT using (n = 5) and non-using (n = 5) women without any notable metabolic diseases which enabled examining the effects of HRT without a disease burden. CRF level was measured with maximal graded exercise test and described as peak oxygen uptake (VO2peak). Pre-exercise test serum samples were used to isolate HDL and the foregoing miRNAs were measured using quantitative polymerase chain reaction (qPCR).\r\nThe studied groups did not differ in HDL-C concentration nor HDL-carried mir-21, -126 and -146a levels. However, there was a positive correlation between miR-126 and serum E2 (p = 0.029). From the studied miRNAs, only miR-146a correlated negatively with VO2peak in HRT using women (p = 0.037) and positively with accelerometer measured leisure time physical activity in non-using women (p = 0.037).\r\nBased on this study the use of HRT does not affect HDL-C nor HDL-carried miR-21, -126 and -146a levels. However, despite of the small sample size, association was found between miR-126 and E2 and the present study supports previously observed association of miR-146a with physical activity. Future studies should focus on examining the effects of menopausal hormonal changes on HDL function.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by Miia Hakanen (mihakane@jyu.fi) on 2020-06-26T05:30:05Z\r\nNo. of bitstreams: 0", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2020-06-26T05:30:06Z (GMT). No. of bitstreams: 0\r\n Previous issue date: 2020", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "79", "language": "", "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.format.mimetype", "value": "application/pdf", "language": null, "element": "format", "qualifier": "mimetype", "schema": "dc"}, {"key": "dc.language.iso", "value": "eng", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.subject.other", "value": "cardiorespiratory fitness", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.title", "value": "The effect of hormone replacement therapy on HDL-cargo of postmenopausal women : special reference to microRNA content", "language": "", "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-202006265121", "language": "", "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Liikuntatieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sport and Health Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Liikunta- ja terveystieteet", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Sport and Health Sciences", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Liikuntal\u00e4\u00e4ketiede", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Sport Medicine", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "yvv.contractresearch.funding", "value": "0", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "openAccess", "language": null, "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "5042", "language": "", "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "estradioli", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "mikro-RNA", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "vaihdevuodet", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "HDL-kolesteroli", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "syd\u00e4n- ja verisuonitaudit", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "hormonihoito", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "estradiol", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "microRNA", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "menopause", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "HDL cholesterol", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "cardiovascular diseases", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "hormone therapy", "language": "", "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.format.content", "value": "fulltext", "language": null, "element": "format", "qualifier": "content", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}, {"key": "dc.rights.accessrights", "value": "", "language": null, "element": "rights", "qualifier": "accessrights", "schema": "dc"}, {"key": "dc.type.okm", "value": "G2", "language": null, "element": "type", "qualifier": "okm", "schema": "dc"}]
|